High-throughput assay for G2 checkpoint inhibitors and identification of the structurally novel compound isogranulatimide

Cancer Research

Volumn 58, Issue 24, 1998, Pages 5701-5706

  Roberge, Michel ^a   Berlinck, Roberto G S ^a,e   Xu, Lin ^a   Anderson, Hilary J ^a   Lim, Lynette Y ^a   Curman, Darko ^a   Stringer, Cheri M ^b   Friend, Stephen H ^b   Davies, Peter ^c   Vincent, Inez ^c   Haggarty, Stephen J ^a   Kelly, Michael T ^d   Britton, Robert ^a   Piers, Edward ^a   Andersen, Raymond J ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Fred Hutchinson Cancer Research Center   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d SeaTek Marine Biotechnology Inc   (Canada)

^e UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING CELL DIVISION; IMIDE;

ARTICLE; BIOASSAY; CANCER INHIBITION; CELL CYCLE G2 PHASE; CELL KILLING; EXTRACT; GAMMA IRRADIATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SCREENING;

ADENOCARCINOMA; ANIMALS; BREAST NEOPLASMS; DNA REPAIR; G2 PHASE; GENES, P53; HUMANS; IMIDAZOLES; INDOLES; LUNG NEOPLASMS; RADIATION-SENSITIZING AGENTS; STAUROSPORINE; SUCCINIMIDES; TUMOR CELLS, CULTURED;

EID: 17444423644     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Hartwell, L., Weinert, T., Kadyk, L., and Garvik, B. Cell cycle checkpoints, genomic integrity, and cancer. Cold Spring Harbor Symp. Quant. Biol., 59: 259-263, 1994.
2. Kaufmann, W. K., and Paules, R. S. DNA damage and cell cycle checkpoints. FASEB J., 10: 238-247, 1996.
3. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular responses to DNA damage. Cancer Res., 57:6304-6311, 1991.
4. Paules, R. S., Levedakou, E. N., Wilson, S. J., Innes, C. L., Rhodes, N., Tlsty, T. D., Galloway, D. A., Donehower, L. A., Tainsky, M. A., and Kaufmann, W. K. Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. Cancer Res., 55: 1763-1773, 1995.
5. Murray, A. W. Creative blocks: cell-cycle checkpoints and feedback controls. Nature (Lend.), 359: 599-604, 1992.
6. Weinert, T., and Lydall, D. Cell cycle checkpoints, genetic instability and cancer. Semin. Cancer Biol., 4: 129-140, 1993.
7. Nurse, P. Checkpoint pathways come of age. Cell, 91: 865-867, 1997.
8. 2 delay in HeLa cells. Cancer Res., 57: 753-758, 1997.
9. 2 arrest. Radiat. Res., 76: 292-307, 1978.
10. Schlegel, R., and Fardee, A. B. Caffeine-induced uncoupling of mitosis from the completion of DNA replication in mammalian cells. Science (Washington DC), 232: 1264-1266, 1986.
11. Downes, C. S., Musk, S. R. R., Watson, J. V., and Johnson, R. T. Caffeine overcomes a restriction point associated with DNA replication, but does not accelerate mitosis. J. Cell Biol., 110: 1855-1859, 1990.
12. cdc2/cyclin B complex formation. Proc. Natl. Acad. Sci. USA, 88: 6843-6847, 1991.
13. Andreassen, P. R., and Margolis, R. L. 2-Aminopurine overrides multiple cell cycle checkpoints in BHK cells. Proc. Natl. Acad. Sci. USA, 89: 2272-2276, 1992.
14. Tam, S. W., and Schlegel, R. Staurosporine overrides checkpoints for mitotic onset in BHK cells. Cell Growth Differ., 3: 811-817, 1992.
15. 2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst. (Bethesda), 88: 956-965, 1996.
16. Roberge, M., Tudan, C., Hung, S. M., Harder, K. W., Jirik, F. R., and Anderson, H. Antitumor drug fostriecin inhibits the mitotic entry checkpoint and protein phosphatases 1 and 2A. Cancer Res., 54: 6115-6121, 1994.
17. Yamashita, K., Yasuda, H., Pines, J., Yasumoto, K., Nishitani, H., Ohtsubo, M., Hunter, T., Sugimura, T., and Nishimoto, T. Okadaic acid, a potent inhibitor of type I and type 2A protein phosphatases, activates Cdc2/Hl kinase and transiently induces a premature mitosis-like state in BHK2I cells. EMBO J., 9: 4331-4338, 1990.